STOCK TITAN

Imagin Medical Selects Lighthouse Imaging as i/Blue(TM) Imaging System Contract Manufacturer

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Imagin Medical has chosen Lighthouse Imaging as the contract manufacturer for its i/Blue Imaging System, a significant advancement towards market approval. Founded in 1984, Lighthouse specializes in FDA-approved medical devices and will assist in the development of Imagin's minimally invasive imaging technology. CEO Jim Hutchens emphasized the importance of this partnership in meeting FDA requirements. The i/Blue system aims to improve cancer visualization during procedures, primarily targeting bladder cancer, thus enhancing detection accuracy and efficiency.

Positive
  • Selection of Lighthouse Imaging as a contract manufacturer, enhancing development efforts for the i/Blue Imaging System.
  • Lighthouse's expertise in FDA-compliant manufacturing processes may expedite the path to market approval.
Negative
  • No assurance that the i/Blue Imaging System will meet performance expectations or gain market approval.

VANCOUVER, BC and BOSTON, MA / ACCESSWIRE / October 7, 2020 / Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) ("Imagin" or the "Company") today announced that it has selected Lighthouse Imaging ("Lighthouse") as the contract manufacturer for the Company's i/Blue Imaging System.

Founded in 1984, Lighthouse Imaging is an FDA registered and ISO 13485:2016 certified contract manufacturer that specializes in providing manufacturing services for medical devices, including full visualization systems and accessories. Lighthouse designs, develops, and manufactures state-of-the-art imaging systems for minimally invasive procedures, including chip-on-tip endoscopic imaging systems; robotic surgery systems; high definition 2D and 3D systems; and reusable and single use systems.

"Selecting a contract manufacturer for our i/Blue Imaging System is a major step toward market approval, especially given the significant validation test data the FDA requires as part of the device approval process," said Jim Hutchens, Imagin's President and CEO. "We would like to thank our contract development firm, Optel, for creating the i/Blue system's unique miniaturized design and progressing the system to this point. We are looking forward to working with Lighthouse to continue to advance i/Blue toward commercialization."

Tom Snyder, CEO of Lighthouse commented, "The Lighthouse engineering team is adept at refining medical device designs and developing manufacturing processes to meet performance, cost, quality and regulatory requirements. Our fully compliant process is proven to be efficient and effective at rapidly developing medical devices. We understand the rigor required to meet the expectations of the FDA for class III devices and we are excited to work with Imagin to drive the i/Blue system through commercialization."

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company's initial focus is bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contact:

Jim Hutchens, President & CEO
Telephone: 833-246-2446

SOURCE: Imagin Medical



View source version on accesswire.com:
https://www.accesswire.com/609546/Imagin-Medical-Selects-Lighthouse-Imaging-as-iBlueTM-Imaging-System-Contract-Manufacturer

FAQ

What is the significance of Imagin Medical selecting Lighthouse Imaging as a manufacturer for the i/Blue Imaging System?

The selection of Lighthouse Imaging is crucial for Imagin Medical as it accelerates the process toward market approval for the i/Blue Imaging System.

What does the i/Blue Imaging System aim to achieve in cancer visualization?

The i/Blue Imaging System is designed to enhance the accuracy and efficiency of cancer detection during minimally invasive procedures, focusing on bladder cancer.

What are the manufacturing credentials of Lighthouse Imaging?

Lighthouse Imaging is FDA registered and ISO 13485:2016 certified, specializing in medical device manufacturing.

When was the announcement about the partnership between Imagin Medical and Lighthouse Imaging made?

The announcement was made on October 7, 2020.

What potential risks are associated with the i/Blue Imaging System?

There is no assurance that the i/Blue Imaging System will work as expected or receive market approval, highlighting inherent uncertainties.

IMAGIN MEDICAL INC

OTC:IMEXF

IMEXF Rankings

IMEXF Latest News

IMEXF Stock Data

118.68k
9.61M
11.27%
Medical Devices
Healthcare
Link
United States of America
Vancouver